TARA Biosystems partners with Scipher Medicine®


NEW YORK & WALTHAM, Massachusetts – (COMMERCIAL THREAD) –TARA Biosystems, a biotechnology company that harnesses human biology and data to transform heart drug discovery, today announced a collaboration with Scipher Medicine, a precision medicine company that provides patients with the most effective treatment. The collaboration will address a critical unmet need for effective therapies in cardiac laminopathies.

Cardiac laminopathies, associated with mutations in the LMNA gene, can lead to electrical and mechanical changes in the heart. These changes can have profound clinical consequences, including cardiomyopathy, sudden cardiac death, and end-stage heart failure. Currently, therapies that correct the underlying pathologies do not exist.

“This collaboration demonstrates the transformative potential of combining biological data with network biology to advance drug discovery and development and unlock new drugs and therapies,” said Misti Ushio, PhD, CEO of TARA Biosystems.

Scipher will leverage human molecular data analyzed by its Spectra â„¢ platform, which includes data from TARA’s BiowireMT II LMNA disease models, to identify new targets for a stratified disease population. This approach aims to identify proteins upstream and downstream of LMNA signaling within the Spectra â„¢ network model. Identified targets will be assessed in TARA’s BiowireMT II, which consists of human heart tissue models derived from induced pluripotent stem cells, including a repertoire of healthy, gene-modified, patient-derived and drug-induced human disease phenotypes.

“The Spectra platform uniquely integrates AI into the protein network of human cells to identify new targets in very complex and debilitating diseases such as laminopathy,” said Slava Akmaev, PhD, CTO and head of therapy at Scipher Medicine. “By interrogating the vicinity of the LMNA network and its relationship to appropriate proteins for targeted therapies, we are confident that we can identify several new and relevant drug targets.”

“The TARA platform is very versatile and can capture robust physiological parameters of human heart function, including contractility, electrophysiology, calcium signaling, structure, as well as genomic, proteomic and metabolic profiles,” said Robert Langer, PhD, Board of Directors of TARA Biosystems. “We believe that the combined efforts of TARA and Scipher have the potential to lead to the development of drugs that enable truly personalized treatment for patients. ”

Under the terms of the partnership, TARA has the exclusive option to advance identified targets towards drug discovery and clinical development. Scipher is eligible to receive milestone payments and royalties. TARA will retain the rights for the development and commercialization of therapeutic products for the selected targets.

“The partnership with TARA is another example of how our disease-agnostic Spectra platform can be applied where new targets are needed most,” added Alif Saleh, CEO of Scipher. “The ability to rapidly validate new targets identified by Spectra on TARA’s human tissue model platform allows us to quickly iterate to identify the most effective targets. ”

About TARA Biosystems, Inc.

New York-based TARA Biosystems harnesses innovations in stem cell biology and tissue engineering to generate in vitro biology that recapitulates human physiology with unprecedented fidelity. Our highly versatile and robust platform captures the integrated physiological parameters of human heart function in a broad repertoire of heart disease phenotypes. Our data facilitate a decisive assessment of the efficacy and risk of new drugs, increasing the likelihood of success and decreasing the long delays associated with traditional drug discovery efforts. New, safer, more effective drugs that are coming to market quickly mean better health and longer lives, and we believe this is benefiting people all over the world. For more information, please visit http://www.tarabiosystems.com.

About spectra

A platform deciphering the complexity of the disease by analyzing large molecular datasets of patients through the unique prism of the human interactome and AI. Drawing on more than a decade of experimental research, the backbone of the platform is the network map of human biology explaining how proteins expressed from the human genome interact to cause specific disease phenotypes, providing the wiring diagram necessary to interpret the dynamic molecular data of individual patients to reveal actual disease biology. Spectra â„¢ is not a model but a representation of disease rooted in experimental human biology and proprietary molecular patient data, allowing us to identify a patient’s unique disease signature, predict drug response to approved drugs and to identify new drug targets in patients unresponsive to existing therapies.

About Scipher Medicine®

Scipher Medicine, a precision immunology company, believes patients deserve straightforward answers to treatment options based on scientifically backed data. Using our proprietary Spectra Network Biology platform and artificial intelligence, we market blood tests that reveal a person’s unique molecular signature of a person’s disease and combine that signature with the most effective therapy, ensuring treatment optimal from day one. The molecular patient data generated from our tests further stimulates the discovery and development of new and more effective therapies. We partner with payers, suppliers and pharmaceutical companies across the healthcare value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook and LinkedIn.

Leave A Reply

Your email address will not be published.